Clinical Trials

364 enrolled

Triple Negative Breast Neoplasms

NCT06205485 2026-04-14

NEO-RT

250 enrolled

Rectal Neoplasms

NCT06393374 2026-04-13

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

1,530 enrolled

Triple Negative Breast Neoplasms

NCT06966700 2026-04-13

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

2,400 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07431281 2026-04-13

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

2,130 enrolled

Adenocarcinoma Of Esophagus, Adenocarcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT06764875 2026-04-09

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

840 enrolled

HER2-positive Gastric Cancer

NCT06958328 2026-04-08

LAP100

356 enrolled

Pancreatic Neoplasms

NCT03801876 2026-04-03

Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer

300 enrolled

Clinical Stage I Esophageal Adenocarcinoma AJCC v8

NCT06901531 2026-04-03

LUCERNA

500 enrolled

Tumor-Agnostic

Adenocarcinoma, Neoplasms

NCT06312176 2026-04-02

MK-2870-010

1,200 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms

NCT07467330 2026-03-12

Dalpiciclib Combined With Endocrine Therapy and Metronomic Capecitabine vs Dalpiciclib Combined With Endocrine Therapy for First-line Treatment

258 enrolled

Breast Neoplasms

NCT06239727 2026-03-06

Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response

593 enrolled

Nasopharyngeal Carcinoma

NCT06532006 2026-02-27

A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

550 enrolled

Stomach Neoplasms

NCT06435429 2026-02-10

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

550 enrolled

Metastatic HER2-positive Breast Cancer

NCT04495088 2026-02-02

Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer

550 enrolled

Rectal Neoplasms

NCT06279364 2026-01-27

A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

524 enrolled

Triple Negative Breast Neoplasms

NCT06957886 2026-01-21

A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer

566 enrolled

HER2-low Breast Cancer

NCT07315750 2026-01-21

A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.

555 enrolled

Stomach Neoplasms

NCT05633654 2026-01-20

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

1,514 enrolled

Triple Negative Breast Neoplasms

NCT06976190 2026-01-20

Magic-C002

446 enrolled

Nasopharyngeal Carcinoma, Recurrence

NCT04095299 2026-01-08

WW3

162 enrolled

Rectal Neoplasms

NCT06686576 2025-12-18

A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer

363 enrolled

Colonic Neoplasms

NCT07071337 2025-12-11

A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy

430 enrolled

Breast Neoplasms

NCT06081959 2025-12-05

Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer

376 enrolled

Breast Neoplasms

NCT07185672 2025-09-22

PReCedeNT

162 enrolled

EndocrineNET

Neuroendocrine Tumors

NCT06079983 2025-09-12

JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects

400 enrolled

Breast Neoplasms

NCT05387603 2025-09-10

START-NET

300 enrolled

EndocrineNET

Neuroendocrine Tumors

NCT06207981 2025-09-02

KANALRAD

310 enrolled

Anus Neoplasms

NCT06490536 2025-08-29

The Sagittarius Trial

700 enrolled

Colonic Neoplasms

NCT06255392 2025-08-15

Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

200 enrolled

Fludzoparib" and Anti-angiogenic

NCT06992882 2025-07-18

A Randomized, Open-label, Multi-center Phase III Study Comparing the Efficacy of Oral Chemotherapy Combined With Trastuzumab Versus Paclitaxel Combined With Trastuzumab in the Adjuvant Treatment of HER2-positive, Lymph Node-negative Early Breast Cancer Patients(ORCHID-PLUS)

2,306 enrolled

HER2-positive Breast Cancer

NCT06507371 2025-06-26

mRCAT-III

170 enrolled

Rectal Neoplasms

NCT06383767 2025-06-19

A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer

378 enrolled

Breast Neoplasms

NCT06629597 2025-02-10

A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma

400 enrolled

Nasopharyngeal Carcinoma

NCT06143553 2024-11-29

Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer

168 enrolled

Breast Neoplasms

NCT06533384 2024-11-04

PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC

310 enrolled

Triple Negative Breast Neoplasms

NCT02355379 2024-07-08

ADAGE

774 enrolled

Colonic Neoplasms

NCT06277050 2024-04-30

Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma

264 enrolled

Nasopharyngeal Carcinoma

NCT06313463 2024-03-15

Study Of Capecitabine Combined With Camrelizumab For Non-pCR TNBC With TLS After Neoadjuvant Chemoterapy

375 enrolled

Breast Neoplasms

NCT01917552 2024-02-28

Adjuvant Capecitabine Versus Observation Alone in Curatively Resected Stage IB Gastric Cancer((KCSG ST14-05): CATALYSIS

870 enrolled

Stomach Neoplasms

NCT01935778 2024-02-28

Compare Adjuvant Chemotherapy of Docetaxel/Capecitabine/Oxliplatin Versus Capecitabine/Oxaliplatin in Advanced Gastric Cancer at Stage IIIb and IV(KCSG ST15-08): TRIUMPH

286 enrolled

Stomach Neoplasms

NCT06177041 2024-02-28

M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.

486 enrolled

Adenocarcinoma, Stomach Neoplasms

NCT06268652 2024-02-20

Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer

302 enrolled

Breast Neoplasms

NCT06017583 2023-10-11

Neoadjuvant Chemotherapy With PD-1 Inhibitors Combined With SIB-IMRT in the Treatment of Locally Advanced Rectal Cancer

48 enrolled

Rectal Neoplasms

NCT05814354 2023-07-20

SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial

530 enrolled

Breast Neoplasms

NCT05212454 2023-04-25

Efficacy of Supplement Adjuvant Capecitabine in HR+/HER2- Breast Cancer Patients With High Risks

400 enrolled

Breast Neoplasms

NCT05797077 2023-04-04

Postoperation Maintenance Therapy for Resectable Liver Metastases of Colorectal Cancer Guided by ctDNA

346 enrolled

Neoplastic Cells, Circulating, Colorectal Neoplasms, Neoplasms, Second Primary

NCT05236972 2022-12-30

PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer

323 enrolled

Colorectal Neoplasms

NCT05342792 2022-04-25

Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma

556 enrolled